1. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR (2007) J Infect Dis 195(3): 425-31
    › Primary publication · 17205482 (PubMed)
  2. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. Hulgan T, Haas DW (2006) J Infect Dis 194(11): 1471-4
    › Primary publication · 17083029 (PubMed)
  3. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. Hulgan T, Hughes M, Sun X, Smeaton LM, Terry E, Robbins GK, Shafer RW, Clifford DB, McComsey GA, Canter JA, Morrow JD, Haas DW (2006) J Acquir Immune Defic Syndr 42(4): 450-4
    › Primary publication · 16791116 (PubMed)
  4. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW (2006) AIDS 20(11): 1503-13
    › Primary publication · 16847405 (PubMed)
  5. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W (2005) J Acquir Immune Defic Syndr 38(3): 277-82
    › Primary publication · 15735444 (PubMed)
  6. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, Shafer RW, Clifford DB, Kallianpur AR, Summar M, Canter JA (2005) AIDS 19(13): 1341-9
    › Primary publication · 16103764 (PubMed)
  7. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR (2005) J Infect Dis 192(6): 950-7
    › Primary publication · 16107946 (PubMed)
  8. The Role of Baseline HIV-1 Resistance Testing in Patients with Established Infection. Chan SY, Hulgan T, D'Aquila RT (2004) Curr Infect Dis Rep 6(3): 243-249
    › Primary publication · 15142489 (PubMed)
  9. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) AIDS 18(18): 2391-400
    › Primary publication · 15622315 (PubMed)
  10. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention. Hulgan T, Rosenbloom ST, Hargrove F, Talbert DA, Arbogast PG, Bansal P, Miller RA, Kernodle DS (2004) J Intern Med 256(4): 349-57
    › Primary publication · 15367178 (PubMed)